http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Research of Job Scheduling With Cloud Based On Trust Mechanism And SFLA
Xiaolan Xie,Ruikun Liu,Guoqing Zhou,Jinsheng Ni 보안공학연구지원센터 2015 International Journal of Grid and Distributed Comp Vol.8 No.1
Job scheduling under the cloud circumstance is the key techniques to impact on frequency of cloud calculation. Trust relationship is an important factor of cloud calculation and job scheduling. In order to satisfy the requirement of quality of cloud calculation service for job scheduling, this article introduced the term of trust mechanism and apply it to cloud calculation and job scheduling. It uses altered SFLA as scheduling strategy, and brings forward a model of job scheduling with cloud circumstance which is based on trust mechanism and SFLA. The simulation results showed that this algorithm with faster convergence speed can increase the trust benefit and accomplish job scheduling task well.
Juan Feng,Xiang Li,Xiaolan Yang,Chun Zhang,Yonghua Yuan,Jun Pu,Yunsheng Zhao,Yanling Xie,Huidong Yuan,Youquan Bu,Fei Liao 대한약학회 2010 Archives of Pharmacal Research Vol.33 No.11
The use of uricase-deficient mammals to screen formulations of engineered uricases as potential drugs for hyperuricemia involves heavy costs and presents a technical bottleneck. Herein, a new practical system was investigated to evaluate the pharmacological significance of a bacterial uricase based on its ability to eliminate uric acid in plasma in vitro, its pharmacokinetics in vivo in healthy rats, and the modeled pharmacodynamics in vivo. This uricase, before and after modification with the monomethyl ether of poly(ethylene glycol)-5000, effectively eliminated uric acid in vitro in rabbit plasma, but its action was susceptible to xanthine inhibition. After intravenous injection of the modified uricase without purification, a bi-exponential model fit well to uricase activities in vivo in the plasma of healthy rats; the half-life of the modified uricase was estimated without interference from the unmodified uricase leftover in the sample and was nearly 100-fold longer than that of the unmodified uricase. Using a model of the elimination of uric acid in vivo taking into account of uricase pharmacokinetics and xanthine inhibition, modeled pharmacodynamics supported that the half-life of uricase and its susceptibility to xanthine are crucial for the pharmacological significance of uricase. Hence,this practical system is desirable for doing preliminary screening of formulations of engineered uricases as potential drugs for hyperuricemia.
Jin, Mingshang,Zhang, Hui,Wang, Jinguo,Zhong, Xiaolan,Lu, Ning,Li, Zhiyuan,Xie, Zhaoxiong,Kim, Moon J.,Xia, Younan American Chemical Society 2012 ACS NANO Vol.6 No.3
<P>Here we report the synthesis of Pd@Cu core–shell nanocubes <I>via</I> epitaxial growth, where the lattice mismatch is 7.1%. The synthesis involved the use of Pd seeds with different shapes (including cubes, cuboctahedra, and octahedra) for the epitaxial growth of Cu shells. Different from the conventional growth mode, Cu atoms initially nucleated only on a few of the many faces of a Pd seed, onto which more Cu atoms were continuously added to generate Cu blocks. Later, the Cu atoms also started to nucleate and grow on other faces of the Pd seed until the entire surface of the seed was covered by a Cu shell. As a result, the Pd seed was rarely located in the center of each core–shell structure. The final product took a cubic shape enclosed by {100} facets regardless of the type of Pd seeds used because of the selective capping of Cu(100) surface by hexadecylamine. The edge lengths of the Pd@Cu nanocubes could be tuned from 50 to 100 nm by varying the amount of Pd seeds while keeping the amount of CuCl<SUB>2</SUB> precursor.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/ancac3/2012/ancac3.2012.6.issue-3/nn2050278/production/images/medium/nn-2011-050278_0001.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nn2050278'>ACS Electronic Supporting Info</A></P>